XS-03 + bevacizumab + FOLFIRI

This therapy is a **combination treatment** consisting of the investigational agent **XS-03**, the monoclonal antibody **bevacizumab**, and the chemotherapy regimen **FOLFIRI**. - **FOLFIRI** is a standard chemotherapy regimen comprising **folinic acid (leucovorin)**, **fluorouracil (5-FU)**, and **irinotecan**. FOLFIRI’s mechanism involves inhibiting DNA synthesis and replication in rapidly dividing cells and is used primarily for metastatic colorectal cancer, among other gastrointestinal cancers[1][2][3][4][5]. - **Bevacizumab** is a monoclonal antibody that inhibits **vascular endothelial growth factor A (VEGF-A)** and thereby blocks angiogenesis essential for tumor growth and metastasis[5]. - **XS-03** is an investigational drug (details on mechanism, developer, and modality are not found in current public domain; it may represent a new molecular entity or a code name under clinical trial evaluation in combination with established agents). - The **combination is designed to use cytotoxic (FOLFIRI), anti-angiogenic (bevacizumab), and experimental mechanisms (XS-03) to target cancer cells through multiple, complementary pathways**. - This combination is likely being evaluated for advanced, metastatic cancers (such as colorectal cancer), especially where combination therapy may improve outcomes over conventional regimens alone[1][5].